Stryker (NYSE:SYK) Earns “Buy” Rating from Citigroup

Stryker (NYSE:SYK)‘s stock had its “buy” rating reaffirmed by investment analysts at Citigroup in a note issued to investors on Wednesday, MarketBeat.com reports. They presently have a $450.00 price objective on the medical technology company’s stock. Citigroup’s target price would suggest a potential upside of 15.65% from the stock’s current price.

Several other analysts have also recently commented on the company. Wells Fargo & Company boosted their price target on Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. Royal Bank of Canada boosted their price target on shares of Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 29th. Needham & Company LLC reiterated a “buy” rating and issued a $442.00 price objective on shares of Stryker in a report on Wednesday, January 29th. The Goldman Sachs Group boosted their target price on Stryker from $384.00 to $427.00 and gave the stock a “neutral” rating in a report on Thursday, January 30th. Finally, Robert W. Baird increased their price target on Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $422.15.

Stryker Stock Performance

NYSE:SYK opened at $389.10 on Wednesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The stock has a market capitalization of $148.47 billion, a PE ratio of 50.14, a P/E/G ratio of 2.93 and a beta of 0.96. Stryker has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The company has a fifty day moving average of $380.06 and a two-hundred day moving average of $370.50.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the firm posted $3.46 EPS. As a group, research analysts forecast that Stryker will post 13.47 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Stryker

Large investors have recently bought and sold shares of the stock. Bernard Wealth Management Corp. purchased a new position in shares of Stryker in the 4th quarter valued at about $188,000. Capital A Wealth Management LLC acquired a new stake in shares of Stryker in the 4th quarter valued at $26,000. Financial Advisory Corp purchased a new stake in shares of Stryker during the 4th quarter worth $310,000. Lakeshore Capital Group Inc. purchased a new position in Stryker in the fourth quarter valued at $850,000. Finally, Heck Capital Advisors LLC acquired a new stake in Stryker in the fourth quarter valued at $662,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.